Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
April 9th, 2019
23K views
Presented herein is a protocol to perform targeted biopsy of the prostate using an MRI-ultrasound fusion system.
Overview
This article presents a protocol for performing targeted prostate biopsies using an MRI-ultrasound fusion system. This innovative method enhances the precision and specificity of biopsy procedures.
Key Study Components
Area of Science
- Urology
- Medical Imaging
- Oncology
Background
- Prostate cancer is a leading cause of cancer in men.
- Traditional biopsy methods may lack precision.
- MRI-ultrasound fusion technology offers improved targeting.
- This method aims to enhance the accuracy of prostate pathology characterization.
Purpose of Study
- To demonstrate a protocol for targeted prostate biopsy.
- To improve biopsy precision and specificity.
- To utilize MRI for better identification of suspicious regions.
Methods Used
- Patient positioning in left lateral decubitus.
- Use of a transrectal ultrasound probe for imaging.
- Administration of local anesthesia for patient comfort.
- Integration of MRI and ultrasound images for accurate targeting.
Main Results
- The protocol allows for precise targeting of suspicious prostate regions.
- Enhanced accuracy in identifying cancerous tissues.
- Improved patient outcomes through better biopsy techniques.
- Successful implementation in a clinical study with significant patient data.
Conclusions
- The MRI-ultrasound fusion system significantly improves biopsy precision.
- This method can lead to better diagnosis and treatment planning.
- Future studies may further validate and refine this approach.
Frequently Asked Questions
What is the main advantage of MRI-ultrasound fusion in biopsies?
It allows for precise targeting of suspicious regions, enhancing biopsy accuracy.
How is patient comfort ensured during the procedure?
Local anesthesia is administered to minimize discomfort during the biopsy.
What imaging technology is used in this biopsy method?
MRI and ultrasound imaging are fused to guide the biopsy procedure.
Can this method be used for repeat biopsies?
Yes, it allows for the removal of previous negative coordinates for accuracy.
What is the significance of the 3D ultrasound model?
It helps ensure that the entire prostate is visible and accurately targeted.
How does motion compensation software enhance the procedure?
It corrects for any movement of the patient or prostate during the biopsy.
Executive Industry Relevance
MRI-ultrasound fusion biopsy addresses a critical gap in prostate cancer diagnosis by enabling precise targeting of MRI-identified lesions, reducing sampling error and improving detection of clinically significant disease. This technology supports early-stage target validation in oncology drug development by providing reproducible, lesion-specific tissue sampling that enhances mechanistic understanding of tumor biology and de-risks translational pathways. Its integration into discovery workflows improves predictive confidence in preclinical models by linking imaging biomarkers to histopathological outcomes.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through targeted sampling of MRI-defined regions of interest, clarifying pathway involvement in prostate carcinogenesis.
- Operational Value: Reduces biological variability by focusing biopsy efforts on histologically confirmed malignant zones, improving reproducibility of molecular profiling.
- Predictive Value: Supports portfolio triage by increasing detection of Gleason ≥7 disease, particularly in high-grade regions of interest, aligning sample quality with clinical relevance.
Screening & Assay Development
- Scientific Value: Generates quantitative, spatially resolved tissue samples that enable assay standardization for biomarker discovery in prostate cancer pathways.
- Operational Value: Improves screening readiness by reducing false negatives and insignificant cancer detection, increasing yield of biologically relevant specimens per procedure.
- Platform Reuse: Supports longitudinal tracking of tumor foci, allowing repeated sampling from identical coordinates to monitor therapeutic response in preclinical models.
Translational & Preclinical Research
- Scientific Value: Provides disease-relevant tissue from imaging-guided targets, strengthening the link between imaging phenotypes and molecular drivers of progression.
- Operational Value: Enables continuity from discovery to preclinical validation by allowing return biopsy to within a few millimeters of prior tumor sites, supporting longitudinal pharmacodynamic studies.
- Risk Mitigation: Reduces mechanistic ambiguity in preclinical models by ensuring that molecular analyses are derived from verified malignant tissue rather than benign or stromal contamination.
Pipeline & Workflow Integration
The method fits within the oncology discovery continuum from target hypothesis testing through lead identification to preclinical validation, where precise lesion sampling informs target confidence and biomarker qualification.
- Discovery Biology: Supports hypothesis testing by enabling molecular analysis of MRI-identified malignant regions, clarifying target engagement and pathway modulation.
- Screening: Enhances assay readiness by delivering reproducible, high-yield tissue samples from defined tumor regions, reducing noise in biomarker and drug response assays.
- Analytics: Generates quantitative histopathological and molecular readouts that allow comparison across treatment conditions and support statistical powering of preclinical studies.
- Translational Research: Connects imaging biomarkers to histopathological outcomes, facilitating qualification of MRI-derived features as predictive indicators of drug response.
- Enterprise Reuse: Functions as a reusable sampling platform for longitudinal studies, enabling tracking of tumor evolution and therapeutic impact over time.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence by reducing sampling bias and improving detection of clinically significant prostate cancer.
- Operational Value: Standardizes biopsy targeting through image fusion, improving inter-operator consistency and reducing procedure-dependent variability.
- Strategic Value: Improves go/no-go decisions by increasing yield of high-grade tumor samples, reducing late-stage failure due to inadequate target validation.
- Portfolio Impact: Enables risk-adjusted advancement by linking lesion grade to molecular phenotype, supporting biomarker-stratified development strategies.
Implementation Considerations
- Requires expertise in urological oncology, medical imaging, and image-guided intervention techniques.
- Depends on MRI-ultrasound fusion workstation hardware, including tracking arms, needle guides, and motion compensation software.
- Necessitates standardization of landmark-based registration protocols across sites to ensure reproducibility of targeting accuracy.
- Requires adaptation of biopsy protocols when applied to preclinical models, including adjustments for probe size, anesthesia, and imaging resolution.
- Limited by prostate motion during procedure, necessitating real-time motion compensation to maintain MRI-US alignment and targeting fidelity.
Biopharma FAQs
Why does lesion-specific sampling improve target validation confidence?
Lesion-specific sampling increases detection of Gleason ≥7 disease, particularly in grade five regions of interest, where 80% of men had high-grade cancer compared to 24% in grade three regions, improving the biological relevance of molecular profiling.
How does rigid and elastic registration support accurate targeting in biopsy workflows?
Rigid registration aligns MRI and ultrasound using shared landmarks, while elastic registration adjusts for prostate deformation from probe compression, maintaining spatial accuracy during targeting.
What quantitative outputs enable longitudinal tracking of tumor foci in active surveillance?
The system allows return biopsy to within a few millimeters of prior tumor sites by using digital markers and 3D reconstruction, enabling precise tracking of changes over time in preclinical or clinical cohorts.
Why is motion compensation necessary when patient or prostate movement occurs during the procedure?
Movement disrupts coregistration of MRI and ultrasound images, causing targeting errors; motion compensation restores alignment by matching live ultrasound to 3D prostate reconstruction using three landmark pairs.
What statistical analysis is required to assess the improvement in clinically significant cancer detection?
Detection rates are compared across biopsy methods—combination, targeted, and systematic—using case counts from clinical studies, such as 89 high-grade cancers detected via combination biopsy versus 74 via targeted and 51 via systematic biopsy in a cohort of 825 patients.
Chapters in this video
0:04
Title
0:39
Patient and Instrument Preparation
2:28
Three-dimensional (3D) Image Acquisition and Magnetic Resonance Image Registration
3:50
Target Acquisition and Motion Compensation
5:29
Prostate Biopsy and Needle Recording
6:54
Results: Representative Assessment of Relationship Between Region of Interest Grade and Presence of Cancer After Combination MRI/TRUS Approach
7:53
Conclusion
